Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dafsolimab Setaritox,Grisnilimab Setaritox
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Philikos Begins Phase 1/2 Study of T-Guard® in Patients with Systemic Sclerosis
Details : T-Guard is designed to rapidly and safely reset the body’s immune system in life-threatening T-cell mediated conditions such as severe autoimmune diseases.
Product Name : T-Guard
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 20, 2025
Lead Product(s) : Dafsolimab Setaritox,Grisnilimab Setaritox
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable